Oseltamivir–zanamivir combination therapy is not superior to zanamivir monotherapy in mice infected with influenza A(H3N2) and A(H1N1)pdm09 viruses
Autor: | Yacine Abed, Guy Boivin, Andrés Pizzorno, Chantal Rhéaume |
---|---|
Rok vydání: | 2014 |
Předmět: |
Oseltamivir
Combination therapy viruses Antiviral Agents Virus chemistry.chemical_compound Influenza A Virus H1N1 Subtype Zanamivir Orthomyxoviridae Infections Weight loss Virology medicine Animals Lung Pharmacology business.industry Influenza A Virus H3N2 Subtype Body Weight virus diseases Influenza a Viral Load biochemical phenomena metabolism and nutrition Survival Analysis respiratory tract diseases 3. Good health Mice Inbred C57BL Disease Models Animal Titer Treatment Outcome chemistry Drug Therapy Combination medicine.symptom business Oseltamivir+Zanamivir medicine.drug |
Zdroj: | Antiviral Research. 105:54-58 |
ISSN: | 0166-3542 |
DOI: | 10.1016/j.antiviral.2014.02.017 |
Popis: | The efficacy of oseltamivir-zanamivir combination therapy compared to that of monotherapy was evaluated in mice infected with influenza A(H3N2) or A(H1N1)pdm09 viruses. For A(H3N2) virus, zanamivir monotherapy and oseltamivir-zanamivir combination showed significant reduction of mean weight loss compared to oseltamivir. Zanamivir monotherapy also conferred decreased mortality, weight loss and lung viral titers (LVT) compared to oseltamivir for A(H1N1)pdm09 wild-type virus. Intermediate benefits were observed for the oseltamivir-zanamivir combination. For the oseltamivir-resistant A(H1N1)pdm09 H275Y virus, the efficacy of oseltamivir-zanamivir was comparable to that of zanamivir and significantly higher than that of oseltamivir in terms of survival, weight loss and LVT. |
Databáze: | OpenAIRE |
Externí odkaz: |
Pro tento záznam nejsou dostupné žádné jednotky.